Trial Outcomes & Findings for Visual Performance of Soft Contact Lenses With Myopia Control Optics (NCT NCT05141448)

NCT ID: NCT05141448

Last Updated: 2025-04-27

Results Overview

Visual performance was calculated as binocular contact lens-corrected distance visual acuity using a Logarithm of Minimal Angle of Resolution (logMAR) visual acuity scale. This was evaluated under high luminance and high contrast conditions (HLHC) at 4 meters from Early Treatment Diabetic Retinopathy Study (ETDRS) charts at the 2-week follow-up visit. Lower visual performance values indicate better vision. A value of 0.0 logMAR is equivalent to 20/20 Snellen Visual Acuity. The average visual performance was reported for each lens type. Binocular visual performance for Run-in lens was measured at 1-week follow-up visit.

Recruitment status

COMPLETED

Target enrollment

79 participants

Primary outcome timeframe

Up to 2-Week Follow-up

Results posted on

2025-04-27

Participant Flow

A total of 79 subjects were enrolled in this study. Of those enrolled, 75 subjects were randomized and dispensed at least one study lens, while 4 subjects failed to meet all eligibility criteria. Of those dispensed, 65 subjects completed the study while, 10 subjects were discontinued from the study.

Participant milestones

Participant milestones
Measure
Run-in Lens/Test 2/Test 1/Control
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore senofilcon A C3 (EMO-114) \[Test 2\] during Period 2, senofilcon A C3 (EMO-118) \[Test 1\] during Period 3 and omafilcon A \[Control\] during Period 4.
Run-in Lens/Test 2/Control/Test 1
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore senofilcon A C3 (EMO-114) \[Test 2\] during Period 2, omafilcon A \[Control\] during Period 3 and senofilcon A C3 (EMO-118) \[Test 1\] during Period 4.
Run-in Lens/Test 1/Test 2/Control
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore senofilcon A C3 (EMO-118) \[Test 1\] during Period 2, senofilcon A C3 (EMO-114) \[Test 2\] during Period 3 and omafilcon A \[Control\] during Period 4.
Run-in Lens/Test 1/Control/Test 2
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore senofilcon A C3 (EMO-118) \[Test 1\] during Period 2, omafilcon A \[Control\] during Period 3 and senofilcon A C3 (EMO-114) \[Test 2\] during Period 4.
Run-in Lens/Control/Test 2/Test 1
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore omafilcon A \[Control\] during Period 2, senofilcon A C3 (EMO-114) \[Test 2\] during Period 3 and senofilcon A C3 (EMO-118) \[Test 1\] during Period 4.
Run-in Lens/Control/Test1/Test2
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore omafilcon A \[Control\] during Period 2, senofilcon A C3 (EMO-118) \[Test 1\] during Period 3 and senofilcon A C3 (EMO-114) \[Test 2\] during Period 4.
Period 1
STARTED
13
13
15
12
11
11
Period 1
COMPLETED
13
12
15
12
10
11
Period 1
NOT COMPLETED
0
1
0
0
1
0
Period 2
STARTED
13
12
15
12
10
11
Period 2
COMPLETED
13
11
15
11
10
9
Period 2
NOT COMPLETED
0
1
0
1
0
2
3
STARTED
13
11
15
11
10
9
3
COMPLETED
11
11
15
11
10
8
3
NOT COMPLETED
2
0
0
0
0
1
4
STARTED
11
11
15
11
10
8
4
COMPLETED
10
11
15
11
10
8
4
NOT COMPLETED
1
0
0
0
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Run-in Lens/Test 2/Test 1/Control
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore senofilcon A C3 (EMO-114) \[Test 2\] during Period 2, senofilcon A C3 (EMO-118) \[Test 1\] during Period 3 and omafilcon A \[Control\] during Period 4.
Run-in Lens/Test 2/Control/Test 1
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore senofilcon A C3 (EMO-114) \[Test 2\] during Period 2, omafilcon A \[Control\] during Period 3 and senofilcon A C3 (EMO-118) \[Test 1\] during Period 4.
Run-in Lens/Test 1/Test 2/Control
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore senofilcon A C3 (EMO-118) \[Test 1\] during Period 2, senofilcon A C3 (EMO-114) \[Test 2\] during Period 3 and omafilcon A \[Control\] during Period 4.
Run-in Lens/Test 1/Control/Test 2
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore senofilcon A C3 (EMO-118) \[Test 1\] during Period 2, omafilcon A \[Control\] during Period 3 and senofilcon A C3 (EMO-114) \[Test 2\] during Period 4.
Run-in Lens/Control/Test 2/Test 1
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore omafilcon A \[Control\] during Period 2, senofilcon A C3 (EMO-114) \[Test 2\] during Period 3 and senofilcon A C3 (EMO-118) \[Test 1\] during Period 4.
Run-in Lens/Control/Test1/Test2
All subjects wore the Run-in lens during Period 1. Subjects randomized to this arm wore omafilcon A \[Control\] during Period 2, senofilcon A C3 (EMO-118) \[Test 1\] during Period 3 and senofilcon A C3 (EMO-114) \[Test 2\] during Period 4.
Period 1
Unsatisfactory Visual Response due to Test Article
0
1
0
0
0
0
Period 1
Subject No Longer Meets Eligibility Criteria
0
0
0
0
1
0
Period 2
Unsatisfactory Visual Response due to Test Article
0
1
0
0
0
0
Period 2
Subject Withdrawn by PI due to Non Compliance to Protocol
0
0
0
0
0
1
Period 2
COVID-19 Related
0
0
0
1
0
1
3
Covid-19 related
2
0
0
0
0
1
4
Unsatisfactory Visual Response due to Test Article
1
0
0
0
0
0

Baseline Characteristics

All subjects dispensed a study lens.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Total
n=75 Participants
All subjects dispensed a study lens.
Age, Continuous
12.6 Years
STANDARD_DEVIATION 2.36 • n=5 Participants • All subjects dispensed a study lens.
Sex: Female, Male
Female
50 Participants
n=5 Participants • All subjects dispensed a study lens.
Sex: Female, Male
Male
25 Participants
n=5 Participants • All subjects dispensed a study lens.
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants • All subjects dispensed a study lens.
Race (NIH/OMB)
Asian
6 Participants
n=5 Participants • All subjects dispensed a study lens.
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
n=5 Participants • All subjects dispensed a study lens.
Race (NIH/OMB)
Black or African American
3 Participants
n=5 Participants • All subjects dispensed a study lens.
Race (NIH/OMB)
White
60 Participants
n=5 Participants • All subjects dispensed a study lens.
Race (NIH/OMB)
More than one race
5 Participants
n=5 Participants • All subjects dispensed a study lens.
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants • All subjects dispensed a study lens.
Region of Enrollment
United States
75 Participants
n=5 Participants • All subjects dispensed a study lens.

PRIMARY outcome

Timeframe: Up to 2-Week Follow-up

Population: All subjects who successfully completed all study visits without a major protocol deviation.

Visual performance was calculated as binocular contact lens-corrected distance visual acuity using a Logarithm of Minimal Angle of Resolution (logMAR) visual acuity scale. This was evaluated under high luminance and high contrast conditions (HLHC) at 4 meters from Early Treatment Diabetic Retinopathy Study (ETDRS) charts at the 2-week follow-up visit. Lower visual performance values indicate better vision. A value of 0.0 logMAR is equivalent to 20/20 Snellen Visual Acuity. The average visual performance was reported for each lens type. Binocular visual performance for Run-in lens was measured at 1-week follow-up visit.

Outcome measures

Outcome measures
Measure
Run-in: Etafilcon A
n=49 Participants
Run-in: etafilcon A (1-Week Follow-up)
Senofilcon A C3 (EMO-114) [Test 2]
n=49 Participants
Subjects that wore senofilcon A C3 (EMO-114) \[Test 2\] during any point of the study.
Senofilcon A C3 (EMO-118) [Test 1]
n=49 Participants
Subjects that wore senofilcon A C3 (EMO-118) \[Test 1\] during any point of the study.
Omafilcon A (MS1D) [Control]
n=49 Participants
Subjects that wore omafilcon A \[Control\] during any point of the study.
Binocular Visual Performance (LogMAR)
-0.10 logMAR
Standard Deviation 0.057
-0.10 logMAR
Standard Deviation 0.063
-0.07 logMAR
Standard Deviation 0.064
-0.11 logMAR
Standard Deviation 0.059

Adverse Events

Run-in: Etafilcon A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Senofilcon A C3 (EMO-114)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Senofilcon A C3 (EMO-118)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Omafilcon A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Principal Research Optometrist

Johnson & Johnson Vision Care, Inc. (JJVC)

Phone: 614-531-6781

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60